CASE REPORT article
Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1589126
This article is part of the Research TopicAdvancing NSCLC Treatment: Overcoming Challenges in Immune Checkpoint Inhibitor TherapyView all 15 articles
Case Report: Pathologic complete response in a patient with simultaneous diagnoses of resectable NSCLC and myeloid neoplasm with PDGFRA rearrangement treated with concurrent neoadjuvant chemoimmunotherapy and imatinib: Translating clinical trial data to real-world practice
Provisionally accepted
- 1Department of Medicine, School of Medicine, University of Maryland, Baltimore, United States
- 2Medical Oncology and Hematology, Medstar Health, Maryland, United States
- 3Department of Pathology, UM Capital Region Health, North Largo, United States
- 4Department of Pathology, School of Medicine, University of Maryland, Baltimore, Maryland, United States
- 5Department of Surgery, School of Medicine, University of Maryland, Baltimore, Maryland, United States
- 6Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, Maryland, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Neoadjuvant chemoimmunotherapy has become an established treatment approach in resectable non-small cell lung cancer (NSCLC). Utilization of neoadjuvant immune checkpoint blockade (ICB) and coordination of care in the real-world setting comes with important challenges, with limited data available for patients with multiple synchronous primary malignancies. This case describes a 57-year-old gentleman with simultaneous diagnoses of resectable stage IIIA NSCLC and PDGFRA-rearranged myeloid neoplasm who received neoadjuvant chemotherapy and nivolumab in combination with imatinib prior to definitive resection. The treatment course was uncomplicated and resulted in a complete pathologic response and resolution of the eosinophilia. Our report highlights the decision-making in pursuing combined systemic therapy of the patient's multiple malignancies and navigating barriers with tissue availability for biomarker testing. Approaches for neoadjuvant immunotherapy in early-stage NSCLC can be successful but will need to be adaptable to reliably manage complex patient presentations in the non-clinical trial setting.
Keywords: NSCLC, PDGFRA, neoadjuvant immunotherapy, Nivolumab, Imatinib
Received: 06 Mar 2025; Accepted: 07 Jul 2025.
Copyright: © 2025 Sussman, Shah, Amin, Fanaroff, Krause, Duong and Rosner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chad B Sussman, Department of Medicine, School of Medicine, University of Maryland, Baltimore, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.